Programme

101Smart Ltd.

Monday 24 January

Chairs: Chris Holcombe & Sarah Vinnicombe

09:05 - 09:25 |
Minimally invasive techniques for therapeutic treatment of cancers
Nisha Sharma
09:25 - 09:45 |
Risk-adapted tailored breast radiotherapy: one size no longer fits all
Charlotte Coles
09:45 - 10:05 |
Risk-adapted axillary surgery including TAD and its practical aspects
Amit Goyal
10:05 - 10:25 |
What's new in DCIS: A grand challenge
Alastair M Thompson
10:25 - 10:45 |
Panel discussion

Chairs: Judith Bliss & Mairead Mackenzie

11:15 - 11:35 |
Pre-surgical provocation tests for clinical trials and management
Mitch Dowsett
11:35 - 11:55 |
Are CDK 4/6 inhibitors ready for clinical use?
Nadia Harbeck
11:55 - 12:15 |
Optimising systemic therapy for women with BRCA mutations: Current knowledge and future directions
Andrew Tutt
12:15 - 12:35 |
Neoadjuvant anti-HER2 therapy enabled risk adaptation: An era to optimise practice
Iain Macpherson
12:35 - 12:55 |
Panel discussion

Chairs: Sarah Pinder & Gareth Evans

13:40 - 14:00 |
Molecular evolution of breast cancer
Lucy Yates
14:00 - 14:20 |
Personalised breast cancer screening
Fiona Gilbert
14:20 - 14:40 |
Past, present and future directions in breast cancer genetics
Douglas Easton
14:40 - 15:00 |
Strategies to prevent breast cancer
Kelly-Anne Phillips
15:00 - 15:20 |
Panel discussion

Chairs: Caroline Wilson and Leena Chagla

15:45 - 16:05 |
Should we be offering next generation sequencing for routine clinical use?
Fabrice André
16:05 - 16:25 |
Immunotherapy for metastatic breast cancer
Peter Schmid
16:25 - 16:45 |
Optimal management and treatment sequencing of ER+ HER2- metastatic breast cancer
Stephen Johnston
16:45 - 17:05 |
Role of surgery in metastatic breast cancer
Nita Nair
17:05 - 17:25 |
Panel discussion

18:00 - 19:00 |
Promotional industry-led symposium organised and funded by Gilead Sciences Ltd.

Tuesday 25 January

Chairs: Ingunn Holen and Thomas Hughes

09:15 - 09:40 |
Co-targeting CDK4/6 and AKT with endocrine therapy overcomes CDK4/6 inhibitor and endocrine therapy resistance in preclinical breast cancer models
Henrik Ditzel
09:40 - 10:05 |
The challenge of modelling of brain metastases - combining in vivo, cell culture and organotypic approaches to investigate brain extravasation
Georgia Mavria
10:05 - 10:30 |
The role of gamma delta T cells in breast cancer development/metastasis
Seth Coffelt
10:30 - 10:55 |
Understanding breast cancer through use of single-cell systems biology
Bernd Bodenmiller

Chairs: Anne Armstrong and Lesley Turner

11:25 - 11:50 |
Unmet need and follow-up
Janet Dunn
11:50 - 12:15 |
Breast Cancer Now's Helpline and patient focused resources
Jane Murphy
12:15 - 12:40 |
Identifying theory and evidence-based psychosocial factors associated with adherence to adjuvant hormonal therapy: understanding individual differences to tailor interventions
Lyndsay Hughes
12:40 - 13:05 |
Supporting women with adherence to endocrine therapy following breast cancer: the SWEET programme
Linda Sharp

Chairs: Baroness Delyth Morgan and Catherine Harper-Wynne

13:50 - 14:00 |
Future of cancer services in the UK
Dame Cally Palmer
14:00 - 14:10 |
Future vision for breast surgery
Dr Raghavan Vidya MS, MD, FRCS
14:10 - 14:20 |
Future vision for radiotherapy
Imogen Locke
14:20 - 14:30 |
Future vision for pathology
Sarah Pinder
14:30 - 14:40 |
Future vision for radiology
Sarah Vinnicombe
14:40 - 14:50 |
Future vision for clinical trials
Judith Bliss
14:50 - 15:00 |
Future vision for systemic therapies
Mark Verrill
15:00 - 15:30 |
Panel discussion

17:30 - 18:00 |
Welcome and Introduction
Mark Verrill
17:30 - 18:00 |
Summary of the RxPONDER publication
Mark Verrill
17:30 - 18:00 |
Case Study Discussion – What does this mean for patients?
Marianne Dillon + Other Speakers